Status:
RECRUITING
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Neuroendocrine Tumors
Somatostatin Receptor-positive Neuroendocrine Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involvin...
Detailed Description
The goal of this research study is to determine if DetectnetTM PET/CT scanning over several days can be used to deliver Lutathera in a safer manner. In this research, participants will be asked to co...
Eligibility Criteria
Inclusion
- Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor
Exclusion
- Unable to lie flat during or tolerate PET/CT or SPECT/CT
- Known incompatibility to CT. SPECT, or PET scans
- Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
Key Trial Info
Start Date :
March 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06122610
Start Date
March 7 2025
End Date
February 1 2026
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin - Madison
Madison, Wisconsin, United States, 53705